Guggenheim Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Guggenheim Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,239	Closed	-$1.26M	–	1773
2025 Q3	$1.26M	Buy	30,239 +1,822	+6%	+$58.3K	0.01%	842
2025 Q2	$817K	Sell	28,417 -2,424	-8%	-$74.9K	0.01%	957
2025 Q1	$1.03M	Buy	30,841 +4,698	+18%	+$175K	0.01%	866
2024 Q4	$1.34M	Sell	26,143 -2,019	-7%	-$113K	0.01%	786
2024 Q3	$1.44M	Sell	28,162 -287	-1%	-$14.8K	0.01%	951
2024 Q2	$1.27M	Buy	28,449 +24,031	+544%	+$1.11M	0.01%	996
2024 Q1	$207K	Buy	+4,418	New	+$173K	﹤0.01%	1784

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Guggenheim Capital's CRNX Position: Q4 2025 in Review

Guggenheim Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 30,239 shares — an estimated $1.26M sold.

Guggenheim Capital first reported a position in CRNX in Q1 2024 and held it in 7 quarters. The position peaked at $1.44M in Q3 2024. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

Guggenheim Capital reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Guggenheim Capital sold 30,239 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $1.26M.
Guggenheim Capital first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 7 quarters.
Guggenheim Capital's Crinetics Pharmaceuticals position peaked at $1.44M in Q3 2024.
240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Guggenheim Capital's 13F filing for Q4 2025, filed 17 Feb 2026.